Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Pediatric Megaloblastic Anemia

  • Author: James L Harper, MD; Chief Editor: Max J Coppes, MD, PhD, MBA  more...
 
Updated: Oct 14, 2015
 

Background

Megaloblastic anemia is an uncommon problem in childhood that is most frequently associated with vitamin deficiency or gastrointestinal disease. The megaloblastic effect is characterized by an aregenerative macrocytic anemia with nuclear dysmaturity, where the nucleus appears immature relative to the cytoplasm because of impaired DNA synthesis. See image below.

Bone marrow aspirate from a patient with untreated Bone marrow aspirate from a patient with untreated pernicious anemia. Megaloblastic maturation of erythroid precursors is shown. Two megaloblasts occupy the center of the slide with a megaloblastic normoblast above. Photo courtesy of Marcel E Conrad, MD.

DNA synthesis is impaired in these cases because of inadequate amounts of metabolically active folate derivatives necessary for DNA base synthesis. Megaloblastic changes affect all 3 hematopoietic cell lines. Thrombocytopenia, leukopenia, and anemia are all observed to varying extents.

The 2 most common causes of megaloblastic anemia are vitamin B-12 (cobalamin) deficiency and folic acid deficiency. Although their clinical settings differ considerably, no hematologic finding can distinguish between the 2 conditions; specific testing is necessary (see Workup). Other less common causes include the use of metabolic inhibitors such as methotrexate and 6-mercaptopurine and certain rare inborn errors such as thiamine-responsive megaloblastic anemia,[1, 2] Lesch-Nyhan syndrome, and hereditary orotic aciduria (see Etiology).

Treatment of megaloblastic anemia depends on the underlying cause. Supplemental folate or vitamin B-12 may be indicated (see Treatment).

Go to Pediatric Chronic Anemia, Anemia of Prematurity, Donath-Landsteiner Hemolytic Anemia, Pediatric Acute Anemia, and Fanconi Anemia for complete information on these topics.

Vitamin B-12 deficiency

Vitamin B-12 is commonly ingested with meat or fish. It binds to salivary haptocorrins, which are digested in the stomach, allowing the cobalamin to bind to intrinsic factor (IF). IF is produced by the parietal cells of the stomach. The IF-B12 complex makes its way to the terminal ileum, where it binds to receptors on the enterocyte. It is transported across the cell and enters the circulation bound to a transport molecule, TC II. The B12-TC II complex is absorbed into cells by endocytosis. In the cell, cobalamin acts as a coenzyme in several reactions, including the synthesis of methionine from homocysteine during the reduction of dihydrofolate to tetrahydrofolate and the conversion of methylmalonyl CoA to succinyl CoA. It is the role of vitamin B-12 in the reduction of folic acid derivatives that results in the megaloblastic changes seen clinically.

Vitamin B-12 deficiency can be caused by decreased ingestion (eg, poor dietary intake), impaired absorption (eg, failure to release B-12 from protein, IF deficiency, chronic pancreatic disease, competitive parasites, intrinsic intestinal disease), or impaired use (eg, congenital enzyme deficiencies, lack of transcobalamin II, administration of nitrous oxide).

Inadequate vitamin B-12 dietary intake is rare in children, though it may be seen in breastfed infants whose mothers are themselves deficient. Pernicious anemia, a common cause of vitamin B-12 deficiency in adults, is rare in childhood. Deficiency of vitamin B-12 activity is usually due to malabsorption or a congenital deficiency of one of the vitamin B-12 carrier proteins. In recent years, vitamin B-12 deficiency has been described in patients with human immunodeficiency virus (HIV) infection, with or without acquired immunodeficiency syndrome (AIDS).

In addition to the hematologic manifestations of vitamin B-12 deficiency, abnormalities of the GI tract and nervous system may also be present. The underlying cause of megaloblastic anemia must be determined in each case. Failure to recognize B-12 deficiency, even in the presence of concomitant folate deficiency, may result in permanent neurologic damage. Treatment with folate alone in these cases may reverse anemia but may allow neurologic damage to progress.

Folate deficiency

Folate is ingested in the diet in many different types of food. It enters the enterocyte and is transported into the portal circulation by a carrier molecule. It circulates in the plasma mostly as 5-methyl tetrahydrofolate (THF). It enters the cell via a carrier (methotrexate competes with this carrier). In the cell, folate binds to and acts as a coenzyme with enzymes responsible for single carbon metabolism.

Folate deficiency can be caused by any of the following:

  • Decreased ingestion (eg, poor dietary intake, alcoholism, infancy)
  • Impaired absorption (eg, intestinal short circuits, celiac sprue, congenital malabsorption, certain drugs such as sulfasalazine)
  • Impaired use (eg, use of folic acid antagonists such as antiepileptic medications, sulfa antibiotics, or methotrexate)
  • Increased requirements (eg, pregnancy, infancy, hyperthyroidism, chronic hemolytic disease, cancer)
  • Increased loss (eg, hemodialysis)

Folic acid is available in a wide variety of food groups. Approximately one third of dietary folate is estimated to come from cereals and grains, another third from fruits and vegetables, and another third from meats and fish. Folic acid deficiency is commonly observed in children who are fed a severely restricted diet. This usually occurs with a diet restricted to goat's milk, which is deficient in folic acid. It may also be observed in children with celiac sprue and other malabsorption disorders that affect the proximal small intestine.

Deficiency of metabolically active folate metabolites is frequently observed in patients who receive antifolate drugs, such as sulfa antibiotics and methotrexate. A relative deficiency of metabolically active folate metabolites may also be observed in patients who are experiencing increased red cell destruction. These patients require a greater amount of folate than is usually present in the diet and develop macrocytic changes in their erythrocytes. Increased folate intake is also important during pregnancy, in which deficiencies have been associated with neural tube defects.

Next

Pathophysiology

Megaloblastic anemia is caused by various DNA synthesis defects. In folate deficiency, purine biosynthesis is affected because folic acid is essential in this process.

Folic acid is essential for purine biosynthesis. Folic acid absorbed from the diet must be activated to produce active tetrahydrofolic acid (THF). THF is necessary for single carbon transfers in the synthesis of pyrimidine nucleotides. Without adequate levels of biologically active THF, the ability to repair and replicate DNA is decreased. Vitamin B-12 is a cofactor for the activation of folic acid in a step that also converts homocysteine to methionine.

In the case of inadequate folic acid intake, THF production is depleted, and DNA synthesis is slowed. The effect on hematopoiesis is to reduce the rate of cell production, resulting in pancytopenia. In the cells that are produced, the effect created is an arrest of nuclear maturation. In other words, the cells that are produced have immature nuclei compared with the degree of maturation of the cytoplasm.

Previous
Next

Etiology

Megaloblastic anemia is most often caused by an acquired lack of vitamin B-12 or lack of folic acid. Inherited abnormalities of the metabolism of these nutrients may be the cause.[3]

Acquired causes of insufficient vitamin B-12 include the following:

  • Inadequate intake in diet
  • Inadequate absorption (deficient IF; deficient absorption from ileum)
  • Impaired transport from the intestine

Acquired causes of insufficient folate include inadequate dietary intake and inadequate absorption from the proximal small intestine. Medications associated with folate deficiency include the following:

  • Sulfonamide antibiotics may interfere with folate metabolism, particularly when they are used on a long-term basis
  • Other antifolate antimetabolite drugs may also cause megaloblastic changes
  • Megaloblastic changes are observed with some frequency with antineoplastic agents, such as methotrexate; azathioprine (Imuran) may also cause megaloblastic changes

Increased metabolic demand (eg, chronic hemolysis, such as in sickle cell disease) or increased loss may also result in insufficient folate.

Congenital absence or deficiency of carrier proteins can cause vitamin B-12 deficiency. These deficiencies occur most commonly as autosomal recessive enzymopathies. These conditions often manifest during infancy and early childhood and are rare but important causes of megaloblastic anemia.

The Imerslund-Grasbeck syndrome of proteinuria and excretion of cobalamin and IF is a rare disorder that arises in early childhood. However, it is an important cause of B-12 deficiency.

Megaloblastic anemia did not develop in children who underwent prolonged exposure to nitrous oxide, according to a study by Duma et al, even though nitrous oxide can raise plasma homocysteine levels in pediatric patients as a result of vitamin B-12 inactivation. Children in the study, who underwent spinal surgery, were exposed to the agent for as long as 8 hours.[4]

Previous
Next

Epidemiology

The prevalence of megaloblastic anemia in childhood has not been established. Vitamin B-12 deficiency is a worldwide problem, however, particularly in the newborn period, due to the combined effects of poor maternal diet and congenital deficiencies of transcobalamin.

Pernicious anemia is a common cause of megaloblastic anemia, especially in persons of European or African descent. Dietary vitamin B-12 deficiency is a serious problem in India, Mexico, Central America, South America, and some areas of Africa. The increase in vegetarianism is related to an increase in vitamin B-12 deficiency and is a particular concern in breastfed infants of vitamin B-12–deficient mothers.

Megaloblastic anemia is observed in all racial and ethnic groups and in both sexes. It is rarely observed in infants, but may occur in infants who breastfeed from mothers who are themselves deficient in vitamin B-12 or in infants with a congenital deficiency of one of the carrier proteins.

Previous
Next

Prognosis

Prognosis depends on the underlying cause of the megaloblastic anemia and the degree of compliance with therapy. Folic acid deficiency is relatively easy to treat; patients usually respond to added folate in their diet. Vitamin B-12 deficiency may be a more significant concern because some patients may require vitamin B-12 injections, with which they may not readily comply. In addition, vitamin B-12 deficiency may be associated with severe neurologic abnormalities that may be long lasting and persist even with appropriate vitamin B-12 therapy.

Morbidity in megaloblastic anemia may include CNS toxicity, including dementia and loss of dorsal column function. Deficiency of vitamin B-12 is usually at the root of this. CNS dysfunction has been described in adult patients who have deficient vitamin B-12 levels in the absence of anemia. Megaloblastic anemia in pregnancy is associated with persistent learning deficits in children.[5, 6] Hyperpigmentation may also be seen.

Decreased numbers of CD4 cells and abnormal CD4/CD8 ratios as well as natural killer (NK) cell numbers have been documented in patients with pernicious anemia. These numbers normalize with cobalamin administration.[7]

Previous
Next

Patient Education

For the new patient, education should focus on the nature of the deficiency causing the anemia and the underlying factors that produce the deficiency. Educate patients or their parents about the neurologic complications of vitamin B-12 deficiency to ensure that they understand the importance of B-12 replacement.

For patient education information, see the Esophagus, Stomach, and Intestine Center; Crohn Disease Center; and Blood and Lymphatic System Center, as well as Celiac Sprue, Crohn Disease, Diet and Nutrition in Crohn Disease, and Anemia.

Previous
 
 
Contributor Information and Disclosures
Author

James L Harper, MD Associate Professor, Department of Pediatrics, Division of Hematology/Oncology and Bone Marrow Transplantation, Associate Chairman for Education, Department of Pediatrics, University of Nebraska Medical Center; Associate Clinical Professor, Department of Pediatrics, Creighton University School of Medicine; Director, Continuing Medical Education, Children's Memorial Hospital; Pediatric Director, Nebraska Regional Hemophilia Treatment Center

James L Harper, MD is a member of the following medical societies: American Society of Pediatric Hematology/Oncology, American Federation for Clinical Research, Council on Medical Student Education in Pediatrics, Hemophilia and Thrombosis Research Society, American Academy of Pediatrics, American Association for Cancer Research, American Society of Hematology

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Steven K Bergstrom, MD Department of Pediatrics, Division of Hematology-Oncology, Kaiser Permanente Medical Center of Oakland

Steven K Bergstrom, MD is a member of the following medical societies: Alpha Omega Alpha, Children's Oncology Group, American Society of Clinical Oncology, International Society for Experimental Hematology, American Society of Hematology, American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

Chief Editor

Max J Coppes, MD, PhD, MBA Executive Vice President, Chief Medical and Academic Officer, Renown Heath

Max J Coppes, MD, PhD, MBA is a member of the following medical societies: American College of Healthcare Executives, American Society of Pediatric Hematology/Oncology, Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Sharada A Sarnaik, MBBS Professor of Pediatrics, Wayne State University School of Medicine; Director, Sickle Cell Center, Associate Hematologist/Oncologist, Children's Hospital of Michigan

Sharada A Sarnaik, MBBS is a member of the following medical societies: American Society of Hematology, American Society of Pediatric Hematology/Oncology, New York Academy of Sciences, Society for Pediatric Research, Children's Oncology Group, American Academy of Pediatrics, Midwest Society for Pediatric Research

Disclosure: Nothing to disclose.

References
  1. Lorber A, Gazit AZ, Khoury A, Schwartz Y, Mandel H. Cardiac manifestations in thiamine-responsive megaloblastic anemia syndrome. Pediatr Cardiol. 2003 Sep-Oct. 24(5):476-81. [Medline].

  2. Olsen BS, Hahnemann JM, Schwartz M, Østergaard E. Thiamine-responsive megaloblastic anaemia: a cause of syndromic diabetes in childhood. Pediatr Diabetes. 2007 Aug. 8(4):239-41. [Medline].

  3. Whitehead VM. Acquired and inherited disorders of cobalamin and folate in children. Br J Haematol. 2006 Jul. 134(2):125-36. [Medline].

  4. Duma A, Cartmill C, Blood J, Sharma A, Kharasch ED, Nagele P. The hematological effects of nitrous oxide anesthesia in pediatric patients. Anesth Analg. 2015 Jun. 120 (6):1325-30. [Medline].

  5. Korenke GC, Hunneman DH, Eber S, Hanefeld F. Severe encephalopathy with epilepsy in an infant caused by subclinical maternal pernicious anaemia: case report and review of the literature. Eur J Pediatr. 2004 Apr. 163(4-5):196-201. [Medline].

  6. Molloy AM, Kirke PN, Brody LC, Scott JM, Mills JL. Effects of folate and vitamin B12 deficiencies during pregnancy on fetal, infant, and child development. Food Nutr Bull. 2008 Jun. 29(2 Suppl):S101-11; discussion S112-5. [Medline].

  7. Erkurt MA, Aydogdu I, Dikilitas M, Kuku I, Kaya E, Bayraktar N, et al. Effects of cyanocobalamin on immunity in patients with pernicious anemia. Med Princ Pract. 2008. 17(2):131-5. [Medline].

  8. Pawlak R, Parrott SJ, Raj S, Cullum-Dugan D, Lucus D. How prevalent is vitamin B(12) deficiency among vegetarians?. Nutr Rev. 2013 Feb. 71(2):110-7. [Medline].

  9. Dror DK, Allen LH. Effect of vitamin B12 deficiency on neurodevelopment in infants: current knowledge and possible mechanisms. Nutr Rev. 2008 May. 66(5):250-5. [Medline].

  10. Ozkale M, Sipahi T. Hematologic and Bone Marrow Changes in Children with Protein-Energy Malnutrition. Pediatr Hematol Oncol. 2013 Aug 29. [Medline].

  11. Dugué B, Ismail E, Sequeira F, Thakkar J, Gräsbeck R. Urinary excretion of intrinsic factor and the receptor for its cobalamin complex in Gräsbeck-Imerslund patients: the disease may have subsets. J Pediatr Gastroenterol Nutr. 1999 Aug. 29(2):227-30. [Medline].

  12. Baumgartner MR. Vitamin-responsive disorders: cobalamin, folate, biotin, vitamins B1 and E. Handb Clin Neurol. 2013. 113:1799-810. [Medline].

  13. Trakadis YJ, Alfares A, Bodamer OA, et al. Update on transcobalamin deficiency: clinical presentation, treatment and outcome. J Inherit Metab Dis. 2014 May. 37 (3):461-73. [Medline].

 
Previous
Next
 
Bone marrow aspirate from a patient with untreated pernicious anemia. Megaloblastic maturation of erythroid precursors is shown. Two megaloblasts occupy the center of the slide with a megaloblastic normoblast above. Photo courtesy of Marcel E Conrad, MD.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.